Genome Editing Market By Type (CRISPR, TALEN, Zinc-Finger Nuclease (ZFN), Meganucleases, and Other), By Application (Cell Line Engineering, Plant Genetic Engineering, and Animal Genetic Engineering), By End User (Pharma and Biotech Companies, CRO (Contract Research Organizations), Research Institutes, and Others), Industry Trends, Estimation & Forecast, 2023-2030

Market Overview

Genome editing is used to modify DNA within a cell. Genome editing can be used to add, alter, and remove DNA in the genome. Genome editing helps to change the DNA in cells or organisms to understand their biology. It is used to modify human blood cells to treat conditions, including leukaemia, AIDS, and treat other infection. Genome editing is also used in agriculture to modify crops to improve their yields and resistance to disease and drought.

Market Dynamics

Potential opportunities in orphan diseases and oncology is boosting the global Genome Editing market. CRISPR/Cas9, ZNF and TALEN are used in gene therapy to cure lethal diseases and genetic diseases through gene modification. Biotech and Pharma companies are adopting these technologies for better disease management as well as the development of personalized medicine. CRISPR/Cas9 system has the potential to treat a broad range of disorders including cancer, viral infection and genetic diseases. Many vendors are using the CRISPR/Cas9 system to enter into the niche genome editing market. TALEN are used to treat X-linked severe combined immunodeficiency, lymphoblastic leukaemia. This technology has generated custom T-cells that are useful to treat cancer, and ZNF produces an HIV-resistant T-cell population and is expected to treat HIV in individuals. The companies and research institute are collaborating to develop new medicines for cancer using CRISPR technology. For instance, AstraZeneca has collaborated with Cancer Research UK to introduce a center of excellence in cancer modelling, genetic screening and big data processing to accelerate the discovery of new cancer medicines. The Functional Genomics Centre will develop CRISPR technology to understand the biology of cancer better, creating biological models that are more reflective of human disease, and advancing computational approaches to analyze big datasets better. Further, Government Initiative for Precision Medicine, Growing Prevalence of Chronic Diseases are key driving factors of the market. However, No Clear Regulatory Framework and Ethical Concerns Related to Genetic Research might hamper the market growth. For instance, The ethical concern related to genetic research in non-human organisms using CRISPR/Cas9 includes risks of inducing mutations, the possibility of ecological disequilibrium for edited organisms release in the environment particularly about gene drives, gaps in regulation, animal welfare, military or terrorist applications and the possibility of xenotransplantation between animals and humans. Moreover, the growing number of genomics projects would provide lucrative opportunities for the market in the coming years.

Market Segmentation
The global Genome Editing market is mainly classified based on Type, Application, End User. Type is further segmented into CRISPR, TALEN, Zinc-Finger Nuclease (ZFN), Meganucleases, Other. By Application, the market is divided into Cell Line Engineering, Plant Genetic Engineering, Animal Genetic Engineering. By End User, the market is further divided into Pharma and Biotech Companies, CRO (Contract Research Organizations), Research Institutes, Others.

CRISPR was dominating the global Genome Editing market by type in 2019. CRISPR is a technology that enables medical researchers to edit parts of the genome by altering, adding or removing sections of the DNA sequence. CRISPR/Cas9 system consists of two parts the Cas9 enzyme and a guide RNA. The strategic collaboration by the companies for research and development of new therapy with CRISPR is boosting the global Genome Editing market. For instance, RS Genomics Ltd and Evolva have signed a non-exclusive license agreement which provides Evolva with worldwide access to ERS’ CRISPR-Cas9 genome editing intellectual property for use in engineering yeast and fungi for production of ingredients for human and animal health, wellness and nutrition, food and beverages, and other industrial applications.

Regional Analysis

Based on geography, the global Genome Editing market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is further divided in the U.S., Canada, and Mexico, whereas Europe consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

North America was dominating the global Genome Editing market in 2019. The increasing clinical studies by the companies on genome editing, strategic collaboration between companies to conduct research and development of new therapy with genome editing, and government initiative to provide support and funding to the companies for testing and development of new therapy are some of the factors boosting the market growth. For instance, The National Institutes of Health have introduced a genome editing research program, Somatic Cell Genome Editing. This program has received approximately $190 million for six years to improve the delivery mechanisms for targeting gene-editing tools in patients, develop assays for testing the safety of the genome editing tools in animal and human cells, develop new and improved genome editors, and assemble a genome editing toolkit containing the resulting knowledge, methods, and tools to be shared with the scientific community.

Competitive landscape

Key players operating in the Genome Editing industry include Thermo Fisher Scientific Inc., Merck Group, New England Biolabs, Inc., GenScript USA Inc., Integrated DNA Technologies Inc., Horizon Discovery Group plc, Origene Technologies Inc., Sangamo Biosciences, Inc., Transposagen Biopharmaceuticals, Inc., CRISPR Therapeutics.

Formation of strategic collaborations and government funding to the companies are the few business strategies adopted by the key companies, with a focus on maintaining a competitive advantage over others. The companies are focused on expanding business activities on a global scale. Promega Corporation has signed an agreement with MilliporeSigma, to access MilliporeSigma’s foundational CRISPR genome-editing technology. According to the agreement, Promega will create new research products for investigating endogenous biology, including for drug development. These tools allow researchers better to read the physiological or natural levels of protein expression, providing a more accurate understanding of protein behavior.

Genome Editing Market Key Segments

By Type
• CRISPR
• TALEN
• Zinc-Finger Nuclease (ZFN)
• Meganucleases
• Other

By Application
• Cell Line Engineering
• Plant Genetic Engineering
• Animal Genetic Engineering

By End-User
• Pharma and Biotech Companies
• CRO (Contract Research Organizations)
• Research Institutes
• Others

Key Global Genome Editing Industry Players

• Thermo Fisher Scientific Inc.
• Merck Group
• New England Biolabs, Inc.
• GenScript USA Inc.
• Integrated DNA Technologies Inc.
• Horizon Discovery Group plc
• Origene Technologies Inc.
• Sangamo Biosciences, Inc.
• Transposagen Biopharmaceuticals, Inc.
• CRISPR Therapeutics

Table of Content

1. Market Introduction
1.1. Executive Summary
1.2. Market Definition
1.3. Market Scope
2. Research Methodology

2.1. Primary Research
2.2. Research Methodology
2.3. Assumptions & Exclusions
2.4. Secondary data sources

3. Genome Editing Market Overview
3.1. Report Segmentation & Scope
3.2. Key Market Trend
3.3. Drivers
3.3.1. Potential opportunities in orphan diseases and oncology
3.3.2. Government Initiative for Precision Medicine
3.3.3. Growing Prevalence of Chronic Diseases
3.4. Restraints
3.4.1. No Clear Regulatory Framework
3.4.2. Ethical Concerns Related to Genetic Research
3.5. Opportunity
3.5.1. The growing number of genomics projects
3.6. Porter’s Five Forces Analysis
3.6.1. Porter’s Five Forces Analysis
3.7. Market Share Analysis

4. Type Overview
4.1. Introduction
4.1.1. Market Size & Forecast
4.2. CRISPR
4.2.1. Market Size & Forecast
4.3. TALEN
4.3.1. Market Size & Forecast
4.4. Zinc-Finger Nuclease (ZFN)
4.4.1. Market Size & Forecast
4.5. Meganucleases
4.5.1. Market Size & Forecast
4.6. Other
4.6.1. Market Size & Forecast

5. Application Overview
5.1. Introduction
5.1.1. Market Size & Forecast
5.2. Cell Line Engineering
5.2.1. Market Size & Forecast
5.3. Plant Genetic Engineering
5.3.1. Market Size & Forecast
5.4. Animal Genetic Engineering
5.4.1. Market Size & Forecast

6. End User Overview
6.1. Introduction
6.1.1. Market Size & Forecast
6.2. Pharma and Biotech Companies
6.2.1. Market Size & Forecast
6.3. CRO (Contract Research Organizations)
6.3.1. Market Size & Forecast
6.4. Research Institutes
6.4.1. Market Size & Forecast

7. Genome Editing Market Regional Overview
7.1. Introduction
7.1.1. Market Size & Forecast
7.2. North America Genome Editing Market
7.2.1. North America Market Size & Forecast, By Country
7.2.2. North America Market Size & Forecast, By Type
7.2.3. North America Market Size & Forecast, By Application
7.2.4. North America Market Size & Forecast, By End User
7.2.5. The U.S.
7.2.5.1. Market Size and Forecast
7.2.6. Canada
7.2.6.1. Market Size and Forecast
7.2.7. Mexico
7.2.7.1. Market Size and Forecast
7.3. Europe Genome Editing Market
7.3.1. Europe Market Size & Forecast, By Country
7.3.2. Europe Market Size & Forecast, By Type
7.3.3. Europe Market Size & Forecast, By Application
7.3.4. Europe Market Size & Forecast, By End User
7.3.5. Germany
7.3.5.1. Market Size and Forecast
7.3.6. France
7.3.6.1. Market Size and Forecast
7.3.7. UK
7.3.7.1. Market Size and Forecast
7.3.8. Italy
7.3.8.1. Market Size and Forecast
7.3.9. Spain
7.3.9.1. Market Size and Forecast
7.3.10. Rest of Europe
7.3.10.1. Market Size and Forecast
7.4. Asia-Pacific Genome Editing Market
7.4.1. Asia-Pacific Market Size & Forecast, By Country
7.4.2. Asia-Pacific Market Size & Forecast, By Type
7.4.3. Asia-Pacific Market Size & Forecast, By Application
7.4.4. Asia-Pacific Market Size & Forecast, By End User
7.4.5. Japan
7.4.5.1. Market Size and Forecast
7.4.6. China
7.4.6.1. Market Size and Forecast
7.4.7. Australia
7.4.7.1. Market Size and Forecast
7.4.8. India
7.4.8.1. Market Size and Forecast
7.4.9. South Korea
7.4.9.1. Market Size and Forecast
7.4.10. Rest of Asia-Pacific
7.4.10.1. Market Size and Forecast
7.5. South America Genome Editing Market
7.5.1. South America Market Size & Forecast, By Country
7.5.2. South America Market Size & Forecast, By Type
7.5.3. South America Market Size & Forecast, By Application
7.5.4. South America Market Size & Forecast, By End User
7.5.5. Brazil
7.5.5.1. Market Size and Forecast
7.5.6. Argentina
7.5.6.1. Market Size and Forecast
7.5.7. Rest of South America
7.5.7.1. Market Size and Forecast
7.6. Middle East & Africa Genome Editing Market
7.6.1. Middle East & Africa Market Size & Forecast, By Country
7.6.2. Middle East & Africa Market Size & Forecast, By Type
7.6.3. Middle East & Africa Market Size & Forecast, By Application
7.6.4. Middle East & Africa Market Size & Forecast, By End User
7.6.5. GCC Countries
7.6.5.1. Market Size and Forecast
7.6.6. Egypt
7.6.6.1. Market Size and Forecast
7.6.7. South Africa
7.6.7.1. Market Size and Forecast
7.6.8. Rest of Middle East & Africa
7.6.8.1. Market Size and Forecast

8. Company Profile
8.1. Thermo Fisher Scientific Inc.
8.1.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
8.1.2. Thermo Fisher Scientific Inc. Product Category, Application, and Specification
8.1.3. Thermo Fisher Scientific Inc. Financial Performance (2016-2018)
8.1.4. Main Business/Business Overview
8.2. Merck Group
8.3. New England Biolabs, Inc.
8.4. GenScript USA Inc.
8.5. Integrated DNA Technologies Inc.
8.6. Horizon Discovery Group plc
8.7. Origene Technologies Inc.
8.8. Sangamo Biosciences, Inc.
8.9. Transposagen Biopharmaceuticals, Inc.
8.10. CRISPR Therapeutics